The guidelines include HLA-B*5701 and abacavir hypersensitivity reaction (ABC-HSR), HLA-B*5801 and allopurinol associated severe cutaneous adverse drug reactions (SCARs) including Stevens–Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS) and HLA-B*5701 and flucloxacillin induced liver injury (DILI). This evidence concerns the gene HLA-B and injury.